Antineovascular therapy, a novel antiangiogenic approach

Bibliography

• CARMELIET P, DORY, HERBERT JM et al: Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 394:485–490.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Fundamental concepts of the angiogenic process. Curr. Mol Med. (2003) 3:643–651.
   PubMed Web of Science ®Google Scholar
• CARMELIET P: Angiogenesis in health and disease. Nat. Med. (2003) 9:653–660.
   PubMed Web of Science ®Google Scholar
• RELF M, LEJEUNE S, SCOTT PA et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57:963–969.
   PubMed Web of Science ®Google Scholar
• KONERDING MA: Ocular angiogenesis: translating preclinical indications to successful clinical development. Expert Opin. Ther. Targets (2004) 8:255–258.
   PubMed Web of Science ®Google Scholar
• ABEDI H, ZACHARY I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. (1997) 272:15442–15451.
   PubMed Web of Science ®Google Scholar
• FERRARA N: VEGF and the quest for tumour angiogenesis factors. Nat. Rev Cancer (2002) 2:795–803.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but Ras-independent Ral-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18:2221–2230.
   PubMed Web of Science ®Google Scholar
• GERBER HP, MCMURTREY A, KOWALSKI J et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. (1998) 273:30336–30343.
   Google Scholar
• BURBRIDGE MF, COGE F, GALIZZI JP et al: The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis (2002) 5:215–226.
   PubMedGoogle Scholar
• HAJITOU A, SOUNNI NE, DEVY L et al.: Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. (2001) 61:3450–3457.
   PubMed Web of Science ®Google Scholar
• SEO DW, LI H, GUEDEZ L et al: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell (2003) 114:171–180.
   PubMed Web of Science ®Google Scholar
• QI JH, EBRAHEM Q, MOORE N et al: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. (2003) 9:407–415.
   PubMed Web of Science ®Google Scholar
• AHONEN M, POUKKULA M, BAKER AH et al.: Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene (2003) 22:2121–2134.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MUROHARA T, SULLIVAN A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964–967.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MASUDA H, TAKAHASHI T et al.: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. (1999) 85:221–228.
   PubMed Web of Science ®Google Scholar
• TAMURA M, UNNO K, YONEZAWA S et al.: In vivo trafficking of endothelial progenitor cells and their possible involvement in tumor neovascularization. Life Sri. (2004) 75:575–584.
   PubMed Web of Science ®Google Scholar
• HEISSIG B, HATTORI K, DIAS S et al.: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 109:625–637.
   PubMed Web of Science ®Google Scholar
• HEISSIG B, WERB Z, RAFII S, HATTORI K: Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb. Haemost. (2003) 90:570–576.
   PubMedGoogle Scholar
• CHANTRAIN CF, SHIMAD H, JODELE S et al.: Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. (2004) 64:1675–1686.
   PubMed Web of Science ®Google Scholar
• RAFII S, LYDEN D, BENEZRA R, HATTORI K, HEISSIG B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev Cancer (2002) 2:826–835.
   PubMed Web of Science ®Google Scholar
• KIMURA H, WEISZ A, OGURA T et al.: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. Biol. Chem. (2001) 276:2292–2298.
   Google Scholar
• SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer (2003) 3:721–732.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669–676.
   PubMed Web of Science ®Google Scholar
• PREWETT M, HUBER J, LI Y et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59:5209–5218.
   PubMed Web of Science ®Google Scholar
• BREKKEN RA, OVERHOLSER JP, STASTNY VA et al: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/F1k-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117–5124.
   PubMed Web of Science ®Google Scholar
• BINETRUY-TOURNAIRE R, DEMANGEL C, MALAVAUD B et al: Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO (2000) 19:1525–1533.
   PubMed Web of Science ®Google Scholar
• ZHANG L, YU D, HICKLIN DJ et al:Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. (2002) 62:2034–2042.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI S, IWATA K, SHIBUYA M: Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem. Biophys. Res. Commun. (2002) 291:554–559.
   PubMed Web of Science ®Google Scholar
• MAHASRESHTI PJ, NAVARRO JG, KATARAM M et al.: Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. (2001) 7:2057–2066.
   PubMed Web of Science ®Google Scholar
• HASUMI Y, MIZUKAMI H, URABE M et al.: Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. (2002) 62:2019–2023.
   PubMed Web of Science ®Google Scholar
• KALLURI R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev Cancer (2003) 3:422–433.
   PubMed Web of Science ®Google Scholar
• JOHN A, TUSZYNSKI G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Patna. Oncol. Res. (2001) 7:14–23.
   PubMedGoogle Scholar
• ZUCKER S, CAO J, CHEN WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 19:6642–6650.
   PubMed Web of Science ®Google Scholar
• LAMBERT V, WIELOCKX B, MUNAUT C et al: MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. (2003) 17:2290–2292.
   PubMed Web of Science ®Google Scholar
• RUPP PA, LITTLE CD: Integrins in vascular development. Circ. Res. (2001) 89:566–572.
   PubMed Web of Science ®Google Scholar
• STUPACK DG, CHERESH DA: Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci. (2002) 115:3729–3738.
   PubMed Web of Science ®Google Scholar
• RUEGG C, DORMOND O, MARIOTTI A: Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim. Biophys. Acta. (2004) 1654:51–67.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, SANDERS LC et al: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85:683–693.
   PubMed Web of Science ®Google Scholar
• HYNES RO: A reevaluation of integrins asregulators of angiogenesis. Nat. Med. (2002) 8:918–921.
   PubMed Web of Science ®Google Scholar
• GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. (2000) 6:3056–3061.
   PubMed Web of Science ®Google Scholar
• KAWAGUCHI M, HOSOTANI R, OHISHI S et al.: A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf-V-) is the potent inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. (2001) 288:711–717.
   PubMedGoogle Scholar
• KUROHANE K, NAMBA Y, OKU N: Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells. Life Sci. (2000) 68:273–281.
   PubMedGoogle Scholar
• KEVIL CG, PAYNE DK, MIRE E, ALEXANDER JS: Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J. Biol. Chem. (1998) 273:15099–15103.
   PubMed Web of Science ®Google Scholar
• BLASCHUK OW, ROWLANDS TM: Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev (2000) 19:1–5.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, LAMPUGNANI MG, MOONS L et al: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 98:147–157.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, COLLEN D: Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann. NY Acad. Sci. (2000) 902:249-262; discussion 262–244.
   Google Scholar
• LIAO F, DOODY JF, OVERHOLSER J et al: Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. (2002) 62:2567–2575.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. (1996) 2:689–692.
   PubMed Web of Science ®Google Scholar
• •This is the first paper that describes angiostatin as a factor that causes and sustains tumour dormancy.
   Google Scholar
• CLAESSON-WELSH L, WELSH M, ITO N et al.: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Nati Acad. Sci. USA (1998) 95:5579–5583.
   PubMed Web of Science ®Google Scholar
• MOSER TL, STACK MS, ASPLIN I et al:Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Li. USA (1999) 96:2811–2816.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI GP, SHARMA MR, ROTHMAN VL, SHARMA MC: Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Micro vasc. Res. (2002) 64:448–462.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277–285.
   Google Scholar
• KIM YM, HWANG S, PYUN BJ et al: Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDRa1k-1. J. Biol. Chem. (2002) 277:27872–27879.
   PubMed Web of Science ®Google Scholar
• IRUELA-ARISPE ML, LUQUE A, LEE N: Thrombospondin modules and angiogenesis. Int. Biochem. Cell Biol. (2004) 36:1070–1078.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-MANZANEQUE JC, LANE TF, ORTEGA MA et al: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Nati Acad. Sci. USA (2001) 98:12485–12490.
   PubMed Web of Science ®Google Scholar
• JIMENEZ B, VOLPERT OV, CRAWFORD SE et al.: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. (2000) 6:41–48.
   PubMed Web of Science ®Google Scholar
• MIAO WM, SENG WL, DUQUETTE M et al: Thrombospondin-1 Type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and - independent mechanisms. Cancer Res. (2001) 61:7830–7839.
   PubMedGoogle Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of 5U5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15:29–41.
   PubMedGoogle Scholar
• FONG TA, SHAWVER LK, SUN L et al.:5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3:401–410.
   PubMed Web of Science ®Google Scholar
• HIRATA A, UEHARA H, IZUMI K et al: Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressi, ZD1839). Cancer Sci (2004) 95:614–618.
   PubMed Web of Science ®Google Scholar
• HIRATA A, OGAWA S, KOMETANI T et al: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. (2002) 62:2554–2560.
   PubMed Web of Science ®Google Scholar
• IZUMI Y, XU L, DI TOMASO E, FUKUMURA D, JAIN RK: Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature (2002) 416:279–280.
   PubMed Web of Science ®Google Scholar
• MORI S, UEDA T, KURATSU S et al: Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int. J. Cancer (1995) 61:148–152.
   PubMed Web of Science ®Google Scholar
• ISOBE N, UOZUMI T, KURISU K, KAWAMOTO K: Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res. (1996) 16:71–76.
   PubMed Web of Science ®Google Scholar
• LIU S, WIDOM J, KEMP CW, CREWS CM, CLARDY J: Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (1998) 282:1324–1327.
   PubMed Web of Science ®Google Scholar
• WANG J, LOU P, HENKIN J: Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. I Cell Biochem. (2000) 77:465–473.
   PubMed Web of Science ®Google Scholar
• MARCHIO S, LAHDENRANTA J, SCHLINGEMANN RO et al: Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell. (2004) 5:151–162.
   PubMed Web of Science ®Google Scholar
• DANIEL TO, LIU H, MORROW JD, CREWS BC, MARNETT LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. (1999) 59:4574–4577.
   PubMed Web of Science ®Google Scholar
• TSUJII M, KAWANO S, TSUJI S et at.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93:705–716.
   Google Scholar
• KIRKPATRICK K, OGUNKOLADE W, ELKAK A et al: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr. Med. Res. Opin. (2002) 18:237–241.
   PubMed Web of Science ®Google Scholar
• LIU XH, KIRSCHENBAUM A, LU M et al.: Prostaglandin E2 induces hypoxia-inducible factor-1 alpha stabilization and nuclear localization in a human prostate cancer cell line. ./. Biol. Chem. (2002) 277:50081–50086.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, KOKI A, SEIBERT K: COX-2 inhibitors. A new class of antiangiogenic agents. Ann. NY Acad. Sci. (1999) 889:84–86.
   PubMed Web of Science ®Google Scholar
• FINE HA, FIGG WD, JAECKLE K et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Clin. Oncol (2000) 18:708–715.
   Web of Science ®Google Scholar
• NG SS, GUTSCHOW M, WEISS M et al.: Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. (2003) 63:3189–3194.
   PubMed Web of Science ®Google Scholar
• ALLEN TM, CULLIS PR: Drug delivery systems: entering the mainstream. Science (2004) 303:1818–1822.
   PubMed Web of Science ®Google Scholar
• OKU N: Anticancer therapy using glucuronate modified long-circulating liposomes. Adv. Drug Deify. Rev. (1999) 40:63–73.
   PubMed Web of Science ®Google Scholar
• OKU N, TOKUDOME Y, ASAI T, TSUKADA H: Evaluation of drug targeting strategies and liposomal trafficking. Corr. Pharm. Des. (2000) 6:1669–1691.
   PubMed Web of Science ®Google Scholar
• SHIMIZU K, TAKADA M, ASAI T et al: Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]amino1-3-hydroxy-7H-indeno12,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol. Pharm. (2002) 25:1385–1387.
   PubMedGoogle Scholar
• SHIMIZU K, TAKADA M, ASAI T et al: Potential usage of liposomal 4beta-aminoalkyl 4' O demethy1-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy. Biol. Pharm. Bull. (2002) 25:783–786.
   PubMedGoogle Scholar
• OKU N, ASAI T, WATANABE K et al: Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene (2002) 21:2662–2669.
   PubMed Web of Science ®Google Scholar
• ••The first paper to propose anti-neovascular therapy, an indirect tumour regression through damaging angiogenic endothelial cells by anticancer agents.
   Google Scholar
• ASAI T, NAGATSUKA M, KUROMI K et al.: Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett. (2002) 510:206–210.
   PubMed Web of Science ®Google Scholar
• ZURITA AJ, ARAP W, PASQUALINI R: Mapping tumor vascular diversity by screening phage display libraries. Control. Release (2003) 91:183–186.
   PubMed Web of Science ®Google Scholar
• TREPEL M, ARAP W, PASQUALINI R: In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol. (2002) 6:399–404.
   PubMed Web of Science ®Google Scholar
• •A review for the biopanning of a phage-displayed peptide library to obtain endothelial cell-specific peptides.
   Google Scholar
• ASAI T, SHIMIZU K, KONDO M et al:Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. (2002) 520:167–170.
   PubMed Web of Science ®Google Scholar
• MAEDA N, TAKEUCHI Y, TAKADA M et al:Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. Control. Release (2004) in press.
   Google Scholar
• PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. (2003) 63:7400–7409.
   PubMed Web of Science ®Google Scholar
• SCHIFFELERS RM, KONING GA, TEN HAGEN TL et al.: Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release (2003) 91:115–122.
   Google Scholar
• OKU N, ASAI T, WATANABE K et al:Anti-neovascular therapy by use of liposomes targeted to angiogenic vessels. Liposome Res. (2003) 13:25–27.
   PubMed Web of Science ®Google Scholar
• KONDO M, ASAI T, KATANASAKA Y et al: Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer (2004) 108:301–306.
   PubMed Web of Science ®Google Scholar
• BROWDER T, BUTTERFIELD CE, KRALING BM et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60:1878–1886.
   PubMed Web of Science ®Google Scholar
• KERBEL RS, KLEMENT G, PRITCHARD KI, KAMEN B: Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol (2002) 13:12–15.
   PubMed Web of Science ®Google Scholar
• MANS, BOCCI G, FRANCIA G etal.: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. (2002) 62:2731–2735.
   Google Scholar
• DOUGHERTY TJ, GOMER CJ, HENDERSON BW etal.: Photodynamic therapy. I Natl Cancer Inst. (1998) 90:889–905.
   PubMed Web of Science ®Google Scholar
• CIULLA TA, DANIS RP, CRISWELL M,PRATT LM: Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin. Investig. Drugs (1999) 8:2173–2182.
   PubMedGoogle Scholar
• KUROHANE K, TOMINAGA A, SATO K et al: Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. (2001) 167:49–56.
   PubMedGoogle Scholar
• ICHIKAWA K, TAKEUCHI Y, YONEZAWA S etal.: Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett. (2004) 205:39–48.
   Google Scholar
• RAN S, DOWNES A, THORPE PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. (2002) 62:6132–6140.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI Y, KUROHANE K, ICHIKAWA K et al: Polycation liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum. Bioconjug. Chem. (2003) 14:790–796.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI Y, ICHIKAWA K, YONEZAWA S et al: Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J. Control. Release (2004) 97:231–240.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI Y, KUROHANE K, ICHIKAWA K et al: Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer (2003) 97:2027–2034.
   PubMedGoogle Scholar
• DUDEK AZ, PAWLAK WZ, KIRSTEIN MN: Molecular targets in the inhibition of angiogenesis. Expert Opin. Ther. Targets (2003) 7:527–541.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N Engl. J. Med. (1971) 285:1182–1186.
   PubMed Web of Science ®Google Scholar